NICE Overturns Bavencio Rejection After Merck/Pfizer Win Appeal On English Funding
Over 800 People With Urothelial Cancer Set To Benefit From Bavencio
As well as now backing the reimbursement of Bavencio for urothelial cancer, the health technology assessment institute has recommended Koselugo, for neurofibromatosis type 1, and Evenity, the osteoporosis drug that will now target over 20,000 people in England and Wales. On the other hand, Piqray has for now been turned down for advanced breast cancer.
You may also be interested in...
In a draft decision NICE, the health technology appraisal body for England and Wales, has declined to recommend Gilead’s Trodelvy for triple negative breast cancer patients.
Bavencio, Taltz, Cosentyx, and Opdivo plus Yervoy were this week also the subject of final recommendations from the health technology assessment body, NICE, on whether or not they should be used on the National Health Service for certain indications.
Novartis has failed to reach a reimbursement agreement to keep its first-in-class advanced breast cancer drug on the German market, but it is pressing on with plans to expand market access for the product across Europe. It is also working on securing regulatory approval to use Piqray in a broader patient population that would carve out a more meaningful place in the relevant treatment pathway.